Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ragini R. Kudchadkar"'
Autor:
Ragini R. Kudchadkar, Jeffrey A. Sosman, Stephen W. Clark, Douglas B. Johnson, Vita Saranga-Perry, Deborah Wallace, W. Bryan Burnette, Patrick J.M. Lavin, David R. Uskavitch, Mark A. Dickson
Publikováno v:
Journal of Clinical Oncology. 33:e122-e124
Autor:
David H. Lawson, Rafi Ahmed, Mohammad K. Khan, Lily Masoumy, Suresh S. Ramalingam, Alice O. Kamphorst, Tahseen H. Nasti, Ragini R. Kudchadkar, Taofeek K. Owonikoko, Melinda I Yushak
Publikováno v:
Journal of Clinical Oncology. 36:e21542-e21542
e21542Background: Brain metastases occur in 15–40% of patients (pts) with systemic cancers, such as lung and melanoma. The standard of care for brain metastases is radiation therapy. Methods to min...
Autor:
Necia Maynard, Ragini R. Kudchadkar, Melinda L. Yushak, Marjorie Mckellar, Michael C. Lowe, Kristin Sieja, Brian Pollack, Stephanie McBrien, David H. Lawson, Mandy L. Ford, Keith A. Delman, Monica Goings
Publikováno v:
Journal of Clinical Oncology. 36:9543-9543
9543Background: cSCC is the second most common skin cancer in the U.S. with over 700,000 new cases and 2000 deaths per year. Though most cSCCs are curable with surgery or radiation, 5% metastasize ...
Autor:
Ibrahima Soumaoro, Ricardo Zwirtes, Ragini R. Kudchadkar, Shailender Bhatia, Shrujal S. Baxi, Janis M. Taube, Tian Chen, Céleste Lebbé, Robert L. Ferris, Asim Amin, William H. Sharfman, Jean-Pierre Delord, Christine H. Chung, Z. Alexander Cao, Suzanne L. Topalian, Michi M. Shinohara, Uwe M. Martens, Julie E. Stein, Paul Nghiem
Publikováno v:
Journal of Clinical Oncology. 36:9505-9505
9505Background: MCC is a rare, aggressive skin cancer commonly associated with the oncogenic Merkel cell polyomavirus (MCPyV). The PD-1/PD-L1 immunosuppressive pathway is often upregulated in MCC, ...
Autor:
Mehmet Asim Bilen, Viraj A. Master, Haydn T. Kissick, David H. Lawson, Ragini R. Kudchadkar, Yuan Liu, Taofeek K. Owonikoko, Dylan J. Martini, Conor E. Steuer, Julie M. Shabto, Suresh S. Ramalingam, Olatunji B. Alese, Bassel F. El-Rayes, R. Donald Harvey, Colleen Lewis, Rathi N. Pillai, Bradley C. Carthon, Christina Wu, Mehmet Akce, Walid L. Shaib
Publikováno v:
Journal of Clinical Oncology. 36:e15022-e15022
e15022Background: Ideal biomarkers for cancer pts receiving IO are currently lacking. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR...
Autor:
Joel Jiang, Rene Gonzalez, Alexandre Avila, Reena Thomas, Ahmad A. Tarhini, Omid Hamid, Stergios J. Moschos, Igor Puzanov, Michael B. Atkins, Ragini R. Kudchadkar, Sheena Demelo, F. Stephen Hodi, Michael A. Postow, Christopher D. Lao, Hussein Abdul-Hassan Tawbi, Nikhil I. Khushalani, Kim Margolin, Marc S. Ernstoff, Alain Algazi, Peter A. Forsyth
Publikováno v:
Journal of Clinical Oncology. 35:9507-9507
9507 Background: Brain metastases (BMts) are a major cause of morbidity/death in MEL. We report the first efficacy data in MEL patients (pts) with BMts who received NIVO+IPI in study CheckMate 204. Methods: In this multicenter US trial (NCT02320058),
Autor:
Danni Yu, Ragini R. Kudchadkar, Robert Wesolowski, Sonya C. Tate, Shande Tang, David Schaer, Richard D. Carvajal, Samuel J. Klempner, Gulam Abbas Manji, John S. Kauh, R. Donald Harvey, Hope S. Rugo, Afshin Dowlati, Omid Hamid
Publikováno v:
Journal of Clinical Oncology. 35:2523-2523
2523 Background: Binding of CSF-1 to the CSF-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. Intratumoral infiltration with macrophages correlates with increased invasiveness, growth, and immunos
Autor:
Ann Chen, Howida Ramadan, Geoffrey T. Gibney, Ragini R. Kudchadkar, Xiuhua Zhao, Zeynep Eroglu, Jane L. Messina, Jeffrey S. Weber, Keiran S.M. Smalley, John M. Koomen, Nikhil I. Khushalani, Joseph Markowitz, Ritin Sharma, Leticia Tetteh, Vernon K. Sondak
Publikováno v:
Journal of Clinical Oncology. 34:9544-9544
9544Background: BRAF inhibitors are clinically active in advanced BRAFV600 mutant melanoma patients, but resistance is common. Multiple resistance mechanisms involve HSP90 clients and preclinical d...
Autor:
Patrick Combemale, Elizabeth Ruth Plummer, Carmen Loquai, Anne Lynn S. Chang, Michael R. Migden, Ragini R. Kudchadkar, Karl D. Lewis, Ralf Gutzmer, Uwe Trefzer, Tingting Yi, Luc Dirix, Dalila Sellami, John T. Lear, Henry Castro, Reinhard Dummer, Martin Kaatz, Manisha Mone, Alexander Guminski, Alexander J. Stratigos
Publikováno v:
Journal of Clinical Oncology. 34:9538-9538
9538Background: Sonidegib 200 mg was approved for use in pts with advanced BCC (aBCC; laBCC + mBCC) or laBCC not amenable to surgery/radiotherapy based on results from BOLT (NCT01327053). Updated d...
Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL)
Autor:
Melissa S. Thebeau, Maria P. Czupryn, Nikhil I. Khushalani, Jeffrey S. Weber, Geoffrey T. Gibney, Joseph Markowitz, Ragini R. Kudchadkar, Young-Chul Kim, Zeynep Eroglu, Allison Richards, Lori McCormick
Publikováno v:
Journal of Clinical Oncology. 34:9586-9586
9586Background: Patients (pts) with resected stage IIIC or IV melanoma are at very high-risk for recurrence and effective strategies for adjuvant therapy are needed. Combination NIVO + IPI yields h...